Qatar is sequencing 350,000 genomes, funding CAR-T cell production at Sidra Medicine, and executing a National Health Strategy targeting 82.6-year life expectancy. With a pharma market growing at nearly 11% CAGR and healthcare commanding 11% of the national budget, here's the full picture of Qatar's
Healthcare Overview: The Qatari Market in 2026 — Precision Medicine, Pharma Growth, and the Health for All Strategy
By Sarah Chen
Category: Healthcare Market Research
Frequently Asked Questions
How big is Qatar's pharmaceutical market?
Qatar's pharmaceutical market reached $4.2 billion in 2025 and is projected to grow to $10.6 billion by 2034, at a CAGR of 10.85% — one of the fastest growth rates in the GCC. The broader healthcare market is valued at $5.8-6.0 billion, with healthcare commanding 11% of national expenditure.
What is the Qatar Genome Programme?
The Qatar Genome Programme (QGP) aims to sequence the genomes of 350,000 inhabitants to build population-scale precision medicine. It has already produced clinical impact: pharmacogenomics is reducing hospital stays from 7 to 3 days for some patients, and genomic screening is enabling early breast cancer detection. Q-Chip, Qatar's first gene chip, enables population-scale genotyping.
What is Qatar's National Health Strategy 2024-2030?
Launched in September 2024, Qatar's 'Health for All' strategy targets increasing life expectancy to 82.6 years, reducing NCD mortality by 36%, and cutting infant mortality to 2 per 1,000 live births. It operates across three pillars: population health, service delivery excellence, and health system efficiency.
Does Qatar have CAR-T cell therapy production?
Yes. In August 2025, Sidra Medicine received funding to develop CAR-T cell production for pediatric oncology, making Qatar one of the first countries in MENA with local advanced cell therapy manufacturing capability. This positions Sidra as a regional hub for precision pediatric oncology.
How does drug registration work in Qatar?
Drug registration in Qatar is managed by the Ministry of Public Health (MOPH). Applications are submitted via eCTD format through the PDCD E-System, with a 12-month review timeline and QAR 150,000 registration fee. A local Qatari-registered agent is mandatory, and fast-track pathways are available for priority therapies.